<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287726</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1297-10</org_study_id>
    <nct_id>NCT03287726</nct_id>
  </id_info>
  <brief_title>What is the Impact of Probiotics on Weight Loss Maintenance in Individuals With Obesity?</brief_title>
  <official_title>Evaluation of the Potential Impact of Probiotics on Weight Loss Maintenance in Individuals With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weight loss maintenance is the biggest challenge in obesity management, with the majority of&#xD;
      weight-reduced individuals experiencing weight regain. The intake of probiotics has been&#xD;
      shown to help in weight loss, but its potential in maximizing weight loss maintenance remains&#xD;
      unknown. Therefore, the main aim of this study is to investigate the impact of probiotic&#xD;
      consumption on weight loss maintenance. Secondary aims are to investigate if the intake of&#xD;
      probiotics influences gut microbiota, cardio-metabolic profile, appetite and inflammatory&#xD;
      markers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body composition</measure>
    <time_frame>9 months</time_frame>
    <description>air displacement plethysmography (BodPod, COSMED, Italy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>appetite suppression</measure>
    <time_frame>9 months</time_frame>
    <description>Online Visual Analogue Scale (VAS) for the measurement of subjective feelings of appetite (hunger, fullness, desire to eat, prospective consumption)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>9 months</time_frame>
    <description>Bioelectrical impedance analysis (BIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting metabolic rate</measure>
    <time_frame>9 months</time_frame>
    <description>indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.</description>
    <arm_group_label>probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  class I or II obesity (30 kg/m2 &lt; BMI &gt; 40 kg/m2)&#xD;
&#xD;
          -  weight stable (&lt;2 kg variation in weight within the last 3 months)&#xD;
&#xD;
          -  not currently dieting to lose weight&#xD;
&#xD;
          -  dietary intervention of 1000 kcal energy restriction for 8 weeks using a powder based&#xD;
             low energy diet product, followed by 4 week weight stabilization phase&#xD;
             (re-introduction of food)&#xD;
&#xD;
          -  women who are either post-menopausal, taking oral contraceptives or with a normal&#xD;
             cycle (28 ± 2 days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  consumption of probiotics 6 months before taking part in the study&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  breast-feeding&#xD;
&#xD;
          -  drug or alcohol abuse within the last two years&#xD;
&#xD;
          -  currently taking medication known to affect appetite or induce weight loss&#xD;
&#xD;
          -  enrolled in another obesity treatment program&#xD;
&#xD;
          -  history of psychological disorders&#xD;
&#xD;
          -  having had bariatric surgery&#xD;
&#xD;
          -  metabolic diseases (such as hypo/hyperthyroidism and diabetes type 1 or 2)&#xD;
&#xD;
          -  eating disorders&#xD;
&#xD;
          -  lactose intolerance&#xD;
&#xD;
          -  gastrointestinal (particularly cholelithiasis), kidney, liver, lung, cardiovascular&#xD;
             disease&#xD;
&#xD;
          -  malignancies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torstein Baade Rø, phd prof</last_name>
    <role>Study Chair</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Martins C, Roekenes J, Salamati S, Gower BA, Hunter GR. Metabolic adaptation is an illusion, only present when participants are in negative energy balance. Am J Clin Nutr. 2020 Nov 11;112(5):1212-1218. doi: 10.1093/ajcn/nqaa220.</citation>
    <PMID>32844188</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Appetite Regulation</keyword>
  <keyword>Gastrointestinal microbiome</keyword>
  <keyword>Caloric Restriction</keyword>
  <keyword>Body weight maintenance</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

